down arrow

NGM Biopharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US62921N1054
USD
1.54
-0.02 (-1.28%)

Apr 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Century Therapeutics, Inc.
Immunome, Inc.
NGM Biopharmaceuticals, Inc.
Aadi Bioscience, Inc.
Sonnet BioTherapeutics Holdings, Inc.
Armata Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Theseus Pharmaceuticals, Inc.
Cyteir Therapeutics, Inc.
PepGen Inc.
Omega Therapeutics, Inc.
Why is NGM Biopharmaceuticals, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-54.55%
EBIT Growth (5y)
-199.25%
EBIT to Interest (avg)
-117.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.18
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.41%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.86
EV to EBIT
0.13
EV to EBITDA
0.13
EV to Capital Employed
-12.83
EV to Sales
-4.22
PEG Ratio
NA
Dividend Yield
99.75%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-92.48%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for NGM Biopharmaceuticals, Inc.
Operating Profit
Highest at USD -29.14
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -27.67
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -27.67 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.33 MM
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for NGM Biopharmaceuticals, Inc.
Net Sales
At USD 0.75 MM has Grown at -97.14%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Debtors Turnover Ratio
Lowest at 1.16% and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Debt-Equity Ratio
Highest at -99.02 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 331.44% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."